ARKG241206P28000
- 0.00
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
CareDx Announced That CareDx Will Partner With TC BioPharm To Perform Pharmacokinetic Analysis Using Its AlloCell Solution In The Achieve Clinical Trial
Top 3 Health Care Stocks That May Collapse This Quarter
10 Health Care Stocks With Whale Alerts In Today's Session
What's Going On With Recursion Pharmaceuticals Stock?
CRISPR Therapeutics Analyst Ratings
Beam Therapeutics Analyst Ratings
Vertex Reports Positive Long-term Data for Casgevy
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Executive Reshuffles: INTC, ZS, ETSY and SEDG
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
Beam Therapeutics Picks Ironwood Pharmaceuticals Finance and Operations Chief as CFO
Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
10 Health Care Stocks Whale Activity In Today's Session
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Follow Nvidia's Lead in Investing in Small-Cap AI Stocks